EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The state of individual participant data sharing for the highest-revenue medicines

Natansh D Modi iD, Lee X Li, Jessica M Logan iD, Michael D Wiese, Ahmad Y Abuhelwa, Ross A McKinnon, Andrew Rowland, Michael J Sorich, Ashley M Hopkins

Clinical Trials · 2025

DOI: 10.1177/17407745241286147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, 2025. Verfasst von Natansh D Modi und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. Hauptthemen laut MEDLINE: Information Dissemination, Clinical Trials as Topic. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Council South Australia, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amid growing emphasis from pharmaceutical companies, advocacy groups, and regulatory bodies for sharing of individual participant data, recent audits reveal limited sharing, particularly for high-revenue medicines. Therefore, this study aimed to assess the individual participant data-sharing eligibility of clinical trials supporting the Food and Drug Administration approval of the top 30 highest-revenue medicines for 2021.

Methods

A cross-sectional analysis was conducted on 316 clinical trials supporting approval of the top 30 revenue-generating medicines of 2021. The study assessed whether these trials were eligible for individual participant data sharing, defined as being publicly listed on a data-sharing platform or confirmed by the trial sponsors as in scope for independent researcher individual participant data investigations. Information was gathered from various sources including ClinicalTrials.gov, the European Union Clinical Trials Register, and PubMed. Key factors such as the trial phase, completion dates, and the nature of the data-sharing process were also examined.

Results

Of the 316 trials, 201 (64%) were confirmed eligible for sharing, meaning they were either publicly listed on a data-sharing platform or confirmed by the trial sponsors as in scope for independent researcher individual participant data investigations. A total of 102 (32%) were confirmed ineligible, and for 13 (4%), the sponsor indicated that a full research proposal would be required to determine eligibility. The analysis also revealed a higher rate of individual participant data sharing among companies that utilized independent platforms, such as Vivli, for managing their individual participant data-sharing process. Trials not marked as completed had significantly lower eligibility for individual participant data sharing.

Conclusion

This study highlights that a substantial portion of trials for top revenue-generating medicines are eligible for individual participant data sharing. However, challenges persist, particularly for trials that are marked as ongoing and for trials where the sharing processes are managed internally by pharmaceutical companies. Data-sharing rates could be improved by adopting open-access individual participant data-sharing models or using independent platforms. Standardizing policies to facilitate immediate individual participant data availability for approved medicines is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Information DisseminationClinical Trials as TopicHumansCross-Sectional StudiesUnited StatesDrug IndustryUnited States Food and Drug AdministrationDrug Approval

Stichwörter der Autor:innen

Individual participant dataclinical trialsdata-sharing policiestransparency

Autor:innen und Institutionen

  • College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
  • Clinical & Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, UAE.

ORCID-Profile: Natansh D Modi, Jessica M Logan

Förderung

  • Cancer Council South Australia
  • National Health and Medical Research Council

Zitieren

APA

Modi, N. D., Li, L. X., Logan, J. M., Wiese, M. D., Abuhelwa, A. Y., McKinnon, R. A., Rowland, A., Sorich, M. J., & Hopkins, A. M. (2025). The state of individual participant data sharing for the highest-revenue medicines. Clinical Trials. https://doi.org/10.1177/17407745241286147

Vancouver

Modi ND, Li LX, Logan JM, Wiese MD, Abuhelwa AY, McKinnon RA, et al. The state of individual participant data sharing for the highest-revenue medicines. Clinical Trials. 2025. doi:10.1177/17407745241286147

BibTeX
@article{Modi2025,
  author = {Modi, Natansh D and Li, Lee X and Logan, Jessica M and Wiese, Michael D and Abuhelwa, Ahmad Y and McKinnon, Ross A and Rowland, Andrew and Sorich, Michael J and Hopkins, Ashley M},
  title = {The state of individual participant data sharing for the highest-revenue medicines},
  journal = {Clinical Trials},
  year = {2025},
  doi = {10.1177/17407745241286147}
}
Kostenlos starten →